A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
NCT06807281
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Atopic Dermatitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 2 to 11 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Pfizer
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Cahaba Dermatology & Skin Health Center · Birmingham, AL
Arkansas · 1
- Arkansas Research Trials · North Little Rock, AR
Florida · 1
- Solutions Through Advanced Research · Jacksonville, FL
Indiana · 1
- Dawes Fretzin Clinical Research Group, LLC · Indianapolis, IN
Missouri · 1
- Saint Louis University · St Louis, MO
South Carolina · 2
- Medical University of South Carolina - South Carolina Translational Research Nexus Clinic · Charleston, SC
- Tribe Clinical Research, LLC · Greenville, SC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.